scispace - formally typeset
D

Dorothee Diogo

Researcher at Harvard University

Publications -  7
Citations -  2272

Dorothee Diogo is an academic researcher from Harvard University. The author has contributed to research in topics: Genome-wide association study & Allele. The author has an hindex of 4, co-authored 4 publications receiving 1884 citations. Previous affiliations of Dorothee Diogo include Broad Institute.

Papers
More filters
Journal ArticleDOI

Genetics of rheumatoid arthritis contributes to biology and drug discovery

Yukinori Okada, +115 more
- 20 Feb 2014 - 
TL;DR: A genome-wide association study meta-analysis in a total of >100,000 subjects of European and Asian ancestries provides empirical evidence that the genetics of RA can provide important information for drug discovery, and sheds light on fundamental genes, pathways and cell types that contribute to RA pathogenesis.
Journal ArticleDOI

Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis

Jing Cui, +72 more
- 28 Mar 2013 - 
TL;DR: A genome-wide association study of more than 2 million common variants in rheumatoid arthritis patients shows that an allele associated with response to etanercept therapy is also associated with CD84 gene expression, and further that CD84 expression correlates with disease activity.
Journal ArticleDOI

Integration of sequence data from a consanguineous family with genetic data from an outbred population identifies PLB1 as a candidate rheumatoid arthritis risk gene

Yukinori Okada, +53 more
- 10 Feb 2014 - 
TL;DR: It is demonstrated that rare, low-frequency and common alleles at one gene locus, phospholipase B1 (PLB1), might contribute to risk of RA in a 4-generation consanguineous pedigree and also in unrelated individuals from the general population (European ancestry).
Journal ArticleDOI

Using human genetics to improve safety assessment of therapeutics

TL;DR: Applications of human genetics to safety studies during drug discovery and development, including assessing the potential for on- and off-target associated adverse events, carcinogenicity risk assessment, and guiding translational safety study designs and monitoring strategies are illustrated.